Biopharma Sustainability Profile
Biopharma, officially known as Biopharma Limited, is a leading player in the biopharmaceutical industry, headquartered in Bangladesh (BD). Established in 2006, the company has rapidly expanded its operations across South Asia, focusing on the development and manufacturing of innovative biopharmaceutical products. Specialising in monoclonal antibodies, biosimilars, and recombinant proteins, Biopharma distinguishes itself through its commitment to quality and affordability, catering to both local and international markets. The company has achieved significant milestones, including regulatory approvals and partnerships that enhance its market position. With a strong emphasis on research and development, Biopharma continues to contribute to the healthcare landscape, making strides in the treatment of various diseases while maintaining a reputation for excellence in the biopharma sector.
DitchCarbon Score
How does Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biopharma's score of 20 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biopharma's reported carbon emissions
Biopharma, headquartered in BD, currently does not report any carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established specific reduction targets or climate pledges. Without emissions data or defined commitments, it is challenging to assess Biopharma's climate impact or initiatives. The absence of reported figures suggests that the company may still be in the early stages of developing its sustainability strategy or may rely on broader industry standards for climate action.
How Carbon Intensive is Biopharma's Industry?
How Carbon Intensive is Biopharma's Location?
Biopharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Biopharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
